Fidelity Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.52B | Buy |
15,023,962
+444,796
| +3% | +$134M | 0.2% | 75 |
|
|
2026
Q1 | $4.82B | Sell |
14,579,166
-1,322,983
| -8% | -$450M | 0.25% | 53 |
|
|
2025
Q4 | $6.32B | Sell |
15,902,149
-865,476
| -5% | -$383M | 0.32% | 35 |
|
|
2025
Q3 | $7.65B | Buy |
16,767,625
+961,104
| +6% | +$391M | 0.4% | 29 |
|
|
2025
Q2 | $5.15B | Buy |
15,806,521
+496,661
| +3% | +$137M | 0.29% | 41 |
|
|
2025
Q1 | $4.13B | Buy |
15,309,860
+1,823,957
| +14% | +$469M | 0.26% | 53 |
|
|
2024
Q4 | $3.17B | Sell |
13,485,903
-1,186,369
| -8% | -$312M | 0.19% | 78 |
|
|
2024
Q3 | $4.04B | Buy |
14,672,272
+2,508,234
| +21% | +$653M | 0.25% | 56 |
|
|
2024
Q2 | $2.96B | Buy |
12,164,038
+2,196,042
| +22% | +$347M | 0.19% | 79 |
|
|
2024
Q1 | $1.49B | Sell |
9,967,996
-344,360
| -3% | -$57.4M | 0.1% | 169 |
|
|
2023
Q4 | $1.97B | Sell |
10,312,356
-969,050
| -9% | -$165M | 0.15% | 107 |
|
|
2023
Q3 | $2B | Sell |
11,281,406
-1,211,094
| -10% | -$231M | 0.17% | 90 |
|
|
2023
Q2 | $2.37B | Sell |
12,492,500
-678,335
| -5% | -$134M | 0.2% | 84 |
|
|
2023
Q1 | $2.64B | Sell |
13,170,835
-341,248
| -3% | -$71.7M | 0.24% | 70 |
|
|
2022
Q4 | $3.21B | Buy |
13,512,083
+562,325
| +4% | +$120M | 0.32% | 54 |
|
|
2022
Q3 | $2.59B | Sell |
12,949,758
-1,374,991
| -10% | -$262M | 0.27% | 62 |
|
|
2022
Q2 | $2.09B | Sell |
14,324,749
-1,720,567
| -11% | -$244M | 0.21% | 82 |
|
|
2022
Q1 | $2.62B | Sell |
16,045,316
-1,894,704
| -11% | -$289M | 0.21% | 77 |
|
|
2021
Q4 | $3.04B | Buy |
17,940,020
+113,092
| +0.6% | +$21M | 0.22% | 64 |
|
|
2021
Q3 | $3.37B | Buy |
17,826,928
+195,199
| +1% | +$36.6M | 0.27% | 57 |
|
|
2021
Q2 | $2.99B | Buy |
17,631,729
+81,828
| +0.5% | +$12M | 0.23% | 66 |
|
|
2021
Q1 | $2.48B | Buy |
17,549,901
+1,457,954
| +9% | +$219M | 0.21% | 80 |
|
|
2020
Q4 | $2.09B | Sell |
16,091,947
-376,981
| -2% | -$50.3M | 0.19% | 93 |
|
|
2020
Q3 | $2.4B | Sell |
16,468,928
-605,703
| -4% | -$86.1M | 0.24% | 68 |
|
|
2020
Q2 | $2.53B | Buy |
17,074,631
+269,322
| +2% | +$36.3M | 0.28% | 52 |
|
|
2020
Q1 | $1.83B | Buy |
16,805,309
+84,934
| +0.5% | +$9.8M | 0.25% | 75 |
|
|
2019
Q4 | $1.93B | Buy |
16,720,375
+39,228
| +0.2% | +$3.91M | 0.21% | 86 |
|
|
2019
Q3 | $1.34B | Buy |
16,681,147
+700,631
| +4% | +$55.4M | 0.16% | 122 |
|
|
2019
Q2 | $1.16B | Buy |
15,980,516
+34,850
| +0.2% | +$2.67M | 0.14% | 139 |
|
|
2019
Q1 | $1.49B | Buy |
15,945,666
+791,113
| +5% | +$66.2M | 0.18% | 107 |
|
|
2018
Q4 | $1.1B | Buy |
15,154,553
+54,637
| +0.4% | +$4.2M | 0.15% | 128 |
|
|
2018
Q3 | $1.32B | Buy |
15,099,916
+21,555
| +0.1% | +$2.17M | 0.15% | 130 |
|
|
2018
Q2 | $1.49B | Buy |
15,078,361
+52,653
| +0.4% | +$5.22M | 0.17% | 104 |
|
|
2018
Q1 | $1.79B | Buy |
15,025,708
+150,087
| +1% | +$19.3M | 0.21% | 95 |
|
|
2017
Q4 | $1.89B | Buy |
14,875,621
+1,115,616
| +8% | +$140M | 0.22% | 83 |
|
|
2017
Q3 | $1.62B | Buy |
13,760,005
+36,852
| +0.3% | +$3.15M | 0.2% | 103 |
|
|
2017
Q2 | $1.09B | Buy |
13,723,153
+815,270
| +6% | +$52.1M | 0.14% | 154 |
|
|
2017
Q1 | $662M | Buy |
12,907,883
+35,803
| +0.3% | +$1.65M | 0.08% | 249 |
|
|
2016
Q4 | $482M | Buy |
12,872,080
+13,385
| +0.1% | +$560K | 0.06% | 330 |
|
|
2016
Q3 | $872M | Buy |
12,858,695
+24,615
| +0.2% | +$1.74M | 0.12% | 188 |
|
|
2016
Q2 | $712M | Buy |
12,834,080
+30,785
| +0.2% | +$1.94M | 0.1% | 216 |
|
|
2016
Q1 | $804M | Buy |
12,803,295
+92,939
| +0.7% | +$6.18M | 0.11% | 187 |
|
|
2015
Q4 | $1.2B | Buy |
12,710,356
+18,087
| +0.1% | +$1.68M | 0.16% | 128 |
|
|
2015
Q3 | $1.02B | Buy |
12,692,269
+49,865
| +0.4% | +$5.54M | 0.15% | 145 |
|
|
2015
Q2 | $1.52B | Buy |
12,642,404
+78,383
| +0.6% | +$9.37M | 0.19% | 105 |
|
|
2015
Q1 | $1.31B | Buy |
12,564,021
+1,024,358
| +9% | +$104M | 0.17% | 138 |
|
|
2014
Q4 | $1.12B | Buy |
11,539,663
+86,441
| +0.8% | +$8.01M | 0.15% | 149 |
|
|
2014
Q3 | $894M | Buy |
11,453,222
+120,214
| +1% | +$7.75M | 0.12% | 183 |
|
|
2014
Q2 | $716M | Buy |
11,333,008
+1,745,486
| +18% | +$104M | 0.1% | 223 |
|
|
2014
Q1 | $644M | Buy |
9,587,522
+74,711
| +0.8% | +$5.78M | 0.09% | 249 |
|
|
2013
Q4 | $612M | Buy |
9,512,811
+70,011
| +0.7% | +$4.18M | 0.09% | 257 |
|
|
2013
Q3 | $604M | Buy |
9,442,800
+117,145
| +1% | +$5.84M | 0.09% | 256 |
|
|
2013
Q2 | $289M | Buy |
+9,325,655
| New | +$248M | 0.05% | 435 |
|
Other funds holding ALNY
Fidelity Investments's ALNY Position: Q2 2026 in Review
Fidelity Investments increased its Alnylam Pharmaceuticals (ALNY) stake by 3.1% in Q2 2026, buying an estimated $134M and bringing the position to 15,023,962 shares worth $4.52B. The position accounts for 0.2% of the portfolio, ranked #75.
Fidelity Investments first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.65B in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Fidelity Investments held 15,023,962 shares of Alnylam Pharmaceuticals worth $4.52B as of Q2 2026.
- Fidelity Investments bought 444,796 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $134M.
- Alnylam Pharmaceuticals made up 0.2% of Fidelity Investments's portfolio in Q2 2026, its #75 holding.
- Fidelity Investments first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Fidelity Investments's Alnylam Pharmaceuticals position peaked at $7.65B in Q3 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.